PTGX Protagonist Therapeutics, Inc.
Healthcare$99.19-2.76%ClosedMarket Cap: $6.38B
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
9.85
P/S
86.13
EV/EBITDA
-46.25
DCF Value
$-9.51
FCF Yield
-1.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.5%
Operating Margin
-192.4%
Net Margin
-154.9%
ROE
-17.8%
ROA
-16.4%
ROIC
-21.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $56.4M | 99.3% | $-3.6M | $3.8M | $— | — |
| Q4 null | $7.4M | 100.0% | $-50.4M | $-44.4M | $— | — |
| FY null | $46.0M | 97.3% | $-158.1M | $-130.1M | $— | — |
| Q3 null | $4.7M | 100.0% | $-46.4M | $-39.3M | $— | — |
| Q2 null | $5.5M | 100.0% | $-42.0M | $-34.8M | $— | — |
| Q1 null | $28.3M | 100.0% | $-19.3M | $-11.7M | $— | — |
| Q4 null | $170.6M | 100.0% | $126.8M | $131.7M | $— | — |
| FY null | $434.4M | 100.0% | $252.8M | $275.2M | $— | — |
| Q3 null | $4.7M | 100.0% | $-41.5M | $-33.2M | $— | — |
| Q2 null | $4.2M | 100.0% | $-38.8M | $-30.6M | $— | — |
| Q1 null | $255.0M | 100.0% | $206.3M | $207.3M | $— | — |
| Q4 2023 | $60.0M | 100.0% | $23.0M | $27.3M | $0.44 | — |